Virtual Reality-Reward Training (VR-RT) for Depression

Phase-Based Progress Estimates
University of California, Los Angeles, Los Angeles, CA
Depression+2 More
Virtual Reality-Reward Training (VR-RT) - Behavioral
All Sexes
What conditions do you have?

Study Summary

The purpose of this study is to compare the effects of Virtual Reality-Reward Training (VR-RT) with an active control condition, Virtual Reality-Memory Training (VR-MT), on positive affect and other clinical symptoms. VR-Reward Training is a novel intervention aimed at enhancing savoring of positive experiences among individuals with depression and low positive affect through guided imaginal recounting following immersion in positive VR experiences. Target enrollment is 80 male and female participants with low positive affect, depression, and impaired functioning, who are at least 18 years old, who will be randomly assigned to 7 weeks of either Virtual Reality-Reward Training (VR-RT) or Virtual Reality-Memory Training (VR-MT). Participants will complete in-person VR sessions, laboratory assessments, self-report questionnaires as part of the study. The total length of participation is around 3 months.

Eligible Conditions

  • Depression
  • Positive Affect

Treatment Effectiveness

Study Objectives

3 Primary · 7 Secondary · Reporting Duration: Change from baseline to follow-up (Week 12)

Week 12
Behavioral Activation Scale (BAS)
Depression, Anxiety, and Stress Scales (DASS-21)
Effort Reward Trade-off Task
MASQ-AD 14 Item
Modified Probe Detection Task (DOTPROBE)
Positive Valence Systems Scale (PVSS-21)
Positive and Negative Affective Schedule (PANAS)
Sheehan Disability Scale (SDS)
Temporal Experience of Pleasure Scale (TEPS)
The Positive Affect and Negative Affect Schedule-Expanded Form (PANAS X) (General Dimensions Scales)

Trial Safety

Trial Design

2 Treatment Groups

Virtual Reality-Memory Training (VR-MT)
1 of 2
Virtual Reality-Reward Training (VR-RT)
1 of 2
Active Control
Experimental Treatment

80 Total Participants · 2 Treatment Groups

Primary Treatment: Virtual Reality-Reward Training (VR-RT) · No Placebo Group · Phase 1

Virtual Reality-Reward Training (VR-RT)
Experimental Group · 1 Intervention: Virtual Reality-Reward Training (VR-RT) · Intervention Types: Behavioral
Virtual Reality-Memory Training (VR-MT)
ActiveComparator Group · 1 Intervention: Virtual Reality-Memory Training (VR-MT) · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: change from baseline to follow-up (week 12)
Closest Location: University of California, Los Angeles · Los Angeles, CA
Photo of Los Angeles 1Photo of Los Angeles 2Photo of Los Angeles 3
2004First Recorded Clinical Trial
10 TrialsResearching Depression
216 CompletedClinical Trials

Who is running the clinical trial?

University of California, Los AngelesLead Sponsor
1,381 Previous Clinical Trials
6,521,067 Total Patients Enrolled
91 Trials studying Depression
38,501 Patients Enrolled for Depression
Michelle G Craske, Ph.DPrincipal InvestigatorUniversity of California, Los Angeles

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are at least 18 years old.
You have a score of 11 or higher on the DASS-21 depression subscale.
You have a score of 6 or more on the SDS.
You are willing to refrain from initiating psychosocial treatments throughout the duration of the study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.